World Journal of Urology

, Volume 29, Issue 4, pp 465–472 | Cite as

No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study

  • Maximilian Burger
  • Shahrokh F. Shariat
  • Hans-Martin Fritsche
  • Juan Ignacio Martinez-Salamanca
  • Kazumasa Matsumoto
  • Thomas F. Chromecki
  • Vincenzo Ficarra
  • Wassim Kassouf
  • Christian Seitz
  • Armin Pycha
  • Stefan Tritschler
  • Thomas J. Walton
  • Giacomo Novara
Topic Paper



Lymph node dissection (LND) is not routinely performed during radical nephroureterectomy (RNU) in upper tract urothelial carcinomas (UTUC), and its clinical relevance is unclear. The purpose of the present study was to evaluate the impact of LND on clinical outcomes in a large multicenter series of RNU for UTUC.


Detailed data on 785 patients subject to RNU were provided by nine international academic centers. The choice to perform lymphadenectomy was determined by the treating surgeon. All pathology slides were evaluated by dedicated genitourinary pathologists. Univariable and multivariable Cox regression models evaluated the association of nodal status with recurrence-free (RFS) and cancer-specific (CSS) survival.


One hundred and ninety patients had LND. Pathological N stage was pN0 in 17%, pNx in 76%, and pN+ in 7%. The median follow-up period of the entire cohort was 34 months (interquartile range [IQR]: 15–65 months). Overall, five-year RFS and CSS estimates were 72.2 and 76%, respectively. In multivariable Cox regression analyses, pN0/pNx substaging was not an independent predictor of either RFS (hazard ratio [HR]: 1.1; P = 0.631) or CSS (HR: 1.3; P = 0.223). Similar results were obtained in a subgroup analysis limited to patients with organ-confined disease (HR: 0.9; P = 0.907 for RFS; HR: 0.4; P = 0.419 for CSS). Conversely, in patients with locally advanced disease, patients with pN0 disease have significantly better cancer-related outcomes (HR: 0.3; P < 0.001 for RFS; HR: 0.3; P < 0.001 for CSS).


The present series suggests pNx is more significantly associated with a worse prognosis than pN0, but only in patients with locally advanced UTUC.


Lymph node Nephroureterectomy Survival Urothelial carcinoma Lymphadenectomy 



Upper tract urothelial carcinoma


Radical nephroureterectomy


Lymph node dissection


Randomized controlled trials


Lymphovascular invasion


Recurrence-free survival


Cancer-specific survival


Interquartile range


Standard error


Hazard ratio


  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43PubMedCrossRefGoogle Scholar
  2. 2.
    NCCN clinical practice guidelines in oncology: bladder cancer. Including upper tract tumors and urothelial carcinoma of the prostate. V.1.2010. National Comprehensive Cancer Network Web site.
  3. 3.
    Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M, Oosterlinck W (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 Update. Eur UrolGoogle Scholar
  4. 4.
    Cornu JN, Rouprêt M, Carpentier X, Geavlete B, de Medina SG, Cussenot O, Traxer O (2010) Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 28(2):151–156PubMedCrossRefGoogle Scholar
  5. 5.
    Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA (2009) The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 55(4):815–825PubMedCrossRefGoogle Scholar
  6. 6.
    Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S, Studer UE (2008) Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol 179(3):873–878PubMedCrossRefGoogle Scholar
  7. 7.
    Manoharan M, Katkoori D, Kishore TA, Jorda M, Luongo T, Soloway MS (2010) Lymphovascular invasion in radical cystectomy specimen: is it an independent prognostic factor in patients without lymph node metastases? World J Urol 28(2):233–237PubMedCrossRefGoogle Scholar
  8. 8.
    Holmer M, Bendahl PO, Davidsson T, Gudjonsson S, Månsson W, Liedberg F (2009) Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it make a difference? World J Urol 27(4):521–526PubMedCrossRefGoogle Scholar
  9. 9.
    Karl A, Carroll PR, Gschwend JE, Knüchel R, Montorsi F, Stief CG, Studer UE (2009) The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol 55(4):826–835PubMedCrossRefGoogle Scholar
  10. 10.
    Zigeuner R, Pummer K (2008) Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors. Eur Urol 53(4):720–731PubMedCrossRefGoogle Scholar
  11. 11.
    Capitanio U, Shariat SF, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Raman JD, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Fernández MI, Ströbel P, Wheat J, Zigeuner R, Langner C, Waldert M, Oya M, Guo CC, Ng C, Montorsi F, Wood CG, Margulis V, Karakiewicz PI (2009) Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol 56(1):1–9PubMedCrossRefGoogle Scholar
  12. 12.
    Novara G, De Marco V, Gottardo F, Dalpiaz O, Bouygues V, Galfano A, Martignoni G, Patard JJ, Artibani W, Ficarra V (2007) Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centres. Cancer 110(8):1715–1722PubMedCrossRefGoogle Scholar
  13. 13.
    Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, Martínez-Salamanca JI, Seitz C, Lemberger RJ, Burger M, El-Hakim A, Baba S, Martignoni G, Gupta A, Karakiewicz PI, Ficarra V, Shariat SF (2010) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57(6):1064–1067PubMedCrossRefGoogle Scholar
  14. 14.
    Roscigno M, Shariat SF, Freschi M, Margulis V, Karakiewizc P, Suardi N, Remzi M, Zigeuner R, Bolenz C, Kikuchi E, Weizer A, Bensalah K, Sagalowsky A, Koppie TM, Raman J, Fernández M, Ströbel P, Kabbani W, Langner C, Wheat J, Guo CC, Kassouf W, Haitel A, Wood CG, Montorsi F (2009) Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology 74(5):1070–1074PubMedCrossRefGoogle Scholar
  15. 15.
    Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG (2009) Upper tract urothelial carcinoma collaboration the upper tract urothelial carcinoma collaboration. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115(6):1224–1233PubMedCrossRefGoogle Scholar
  16. 16.
    Kondo T, Nakazawa H, Ito F, Hashimoto Y, Toma H, Tanabe K (2007) Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol 178:1212PubMedCrossRefGoogle Scholar
  17. 17.
    Brausi MA, Gavioli M, De Luca G, Verrini G, Peracchia G, Simonini G et al (2007) Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. Eur Urol 52:1414PubMedCrossRefGoogle Scholar
  18. 18.
    Roscigno M, Cozzarini C, Bertini R, Scattoni V, Freschi M, Da Pozzo LF et al (2008) Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol 53:794PubMedCrossRefGoogle Scholar
  19. 19.
    Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, Suardi N, Bertini R, Fernández MI, Mikami S, Isida M, Michel MS, Montorsi F (2009) Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 181(6):2482–2489PubMedCrossRefGoogle Scholar
  20. 20.
    Lughezzani G, Jeldres C, Isbarn H, Shariat SF, Sun M, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI (2010) A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology 75(1):118–124PubMedCrossRefGoogle Scholar
  21. 21.
    Greene FL, Gospodarowicz M, Wittekind C et al (2009) American Joint Committee on Cancer (AJCC) staging manual, 7th edn. Springer, PhiladelphiaGoogle Scholar
  22. 22.
    Mostofi FK, Sobin LH, Torloni H (1973) Histological typing of urinary bladder tumours. World Health Organization, GenevaGoogle Scholar
  23. 23.
    Margulis V, Youssef RF, Karakiewicz PI et al (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184(2):453–458PubMedCrossRefGoogle Scholar
  24. 24.
    Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon. Stage migration, new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312:1604PubMedCrossRefGoogle Scholar
  25. 25.
    Shariat SF, Favaretto RL, Gupta A, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Tritschler S, Baba S, Matsushita K, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Otto W, Karakiewicz PI, Ficarra V, Novara G (1 Oct 2010) Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol [Epub ahead of print]Google Scholar
  26. 26.
    Otto W, Shariat SF, Fritsche HM, Gupta A, Matsumoto K, Kassouf W, Martignoni G, Walton TJ, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Burger M, Karakiewicz PI, Ficarra V, Novara G (20 Jan 2011) Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicentre analysis of 772 patients. World J Urol [Epub ahead of print]Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Maximilian Burger
    • 1
  • Shahrokh F. Shariat
    • 2
  • Hans-Martin Fritsche
    • 1
  • Juan Ignacio Martinez-Salamanca
    • 3
  • Kazumasa Matsumoto
    • 4
  • Thomas F. Chromecki
    • 2
  • Vincenzo Ficarra
    • 5
  • Wassim Kassouf
    • 6
  • Christian Seitz
    • 7
  • Armin Pycha
    • 7
  • Stefan Tritschler
    • 8
  • Thomas J. Walton
    • 9
  • Giacomo Novara
    • 5
  1. 1.Department of Urology, Caritas St. Josef Medical CentreUniversity of RegensburgRegensburgGermany
  2. 2.Weill Medical College of Cornell UniversityNew YorkUSA
  3. 3.Hospital Universitario Puerta de Hierro-MajadahondaUniversidad Autónoma de MadridMadridSpain
  4. 4.Kitasato University School of MedicineSagamiharaJapan
  5. 5.University of PaduaPaduaItaly
  6. 6.McGill University Health CentreMontréalCanada
  7. 7.General Hospital BolzanoBolzanoItaly
  8. 8.Department of UrologyLudwig-Maximilians-UniversityMunichGermany
  9. 9.Derby City General HospitalDerbyUK

Personalised recommendations